Thursday 18 June 2026

The Pharma Letter Podcast — Episode 16 — EQRx plots radical disruption on pricing

Biotechnology
Simon Wentworth
22 July 2022
episode16_big


More on this story...

Biotechnology
CStone up on deal with EQRx for two immune checkpoint Inhibitors
27 October 2020
Biotechnology
EQRx releases positive Phase III trial data on sugemalimab
8 August 2022
Biotechnology
Not so easy to go low with drug prices, EQRx accepts
11 November 2022
Biotechnology
EQRx gets MAA for aumolertinib accepted by EMA
2 December 2022




More ones to watch >




Today's issue

Curium court decision advances therapy plans for GEP-NETs
Pharmaceutical
Curium court decision advances therapy plans for GEP-NETs
18 June 2026
Biotechnology
FDA accepts Roche’s sBLA for Lunsumio and Polivy combo
18 June 2026
Pharmaceutical
J-Pharma and Uniphar advance nanvuranlat into global Phase III trial
18 June 2026
Biosimilars
Samsung Bioepis and Organon expand commercialization of Pyzchiva
18 June 2026
Generics
First generic Xofluza clears US FDA ahead of flu season
18 June 2026
Pharmaceutical
Neurizon locks in Elanco supply for ALS hopeful
18 June 2026
Biotechnology
Biogen expands immunology pipeline with RayThera buy
18 June 2026


Company Spotlight

Edgewise Therapeutics
A Boulder, Colorado-based biotech that has sharpened its focus entirely on cardiovascular disease after divesting its muscular dystrophy franchise to Servier, with oral cardiac sarcomere modulator EDG-7500 now its singular Phase III-bound bet in hypertrophic cardiomyopathy.


More Features in Biotechnology

FDA accepts Roche’s sBLA for Lunsumio and Polivy combo
18 June 2026
Biogen expands immunology pipeline with RayThera buy
18 June 2026
Triveni Bio raises $65 million to advance atopic dermatitis bispecific
18 June 2026
Adaptive Biotechnologies prices $300 million senior notes offering
18 June 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze